|By PR Newswire||
|January 21, 2014 11:37 AM EST||
SAN FRANCISCO, Jan. 21, 2014 /PRNewswire-USNewswire/ -- The International Society for Neurovascular Diseases (ISNVD.org) and The Annette Funicello Research Fund for Neurological Diseases today announced a co-hosted meet & greet with the world's leading doctors in CCSVI research, a revolutionary new treatment for Multiple Sclerosis. This is a never before seen opportunity for physicians, patients and journalists to meet with top doctors in an informal, face-to-face setting.
What: Direct discussions with top doctors in CCSVI research. Doctors from around the globe will be mingling with patients, journalists and medical professionals at a gala dinner and reception held in conjunction with the Annual ISNVD Conference of 2014.
A silent auction will also be held to benefit ISNVD. In addition, Jeff Beal, an Emmy award winning music composer, and the first person treated for CCSVI in the US at Stanford, will be playing music with friends throughout the evening.
Who: Michael Dake, M.D., ISNVD President, Annual Meeting Chair, Stanford University Mark E. Haacke, Ph.D., ISNVD Vice-President, Wayne State University, Paolo Zamboni, M.D., ISNVD Annual Meeting Chairperson, University of Ferarra, Italy, Clive Beggs, Ph.D., ISNVD Chairperson, Publication Committee, University of Bradford, U.K. and others
When: Saturday, February 8, 2014, 7-10:00pm.
Where: Marines' Memorial Club & Hotel, 609 Sutter St., San Francisco, CA 94102
Why: CCSVI is a promising, albeit controversial new treatment for Multiple Sclerosis involving opening obstructed veins with angioplasty. The research is still in its early stages, and there are many questions still unanswered. This gala event gives patients and physicians a rare opportunity to chat face-to-face with the top researchers in the field, while simultaneously supporting upcoming research. Proceeds will go directly to support ISNVD, furthering the promise of this new approach to MS & other neurological diseases.
SOURCE Annette Funicello Research Fund For Neurological Diseases, Inc